347) The study aimed to evaluate the possible contribution of CTLA-4 exon 1 49 A>G polymorphism to the pathogenesis of ITP and its relation to age of disease onset, clinical course, and response to therapy. |
PMID:24023266 DOI:10.1177/1076029613502254 |
2015 Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis |
* Lack of impact of cytotoxic T-lymphocyte antigen 4 gene exon 1 polymorphism on susceptibility to or clinical course of egyptian childhood immune thrombocytopenic purpura. |
- Dysfunctional T-lymphocyte immunity plays an important role in the pathophysiology of immune thrombocytopenic purpura (ITP). Cytotoxic T-lymphocyte antigen 4 (CTLA-4)-a surface marker expressed on T regulatory cells and activated T lymphocytes-is a negative modulator of T-cell responses. Polymorphisms of the CTLA-4 may alter the level of antigen expression and hence may influence immune regulation. The study aimed to evaluate the possible contribution of CTLA-4 exon 1 49 AThe study aimed to evaluate the possible contribution of CTLA-4 exon 1 49 A>G polymorphism to the pathogenesis of ITP and its relation to age of disease onset, clinical course, and response to therapy.gt;G polymorphism to the pathogenesis of ITP and its relation to age of disease onset, clinical course, and response to therapy. Genotyping of CTLA-4 exon 1 49 A>G was performed in 100 pediatric patients with ITP and 259 healthy individuals by polymerase chain reaction-restricted fragment length polymorphism. No significant differences existed in genotype or allele distributions between patients and controls for the studied polymorphism. Comparable genotypes and allele frequencies were obtained between the 2 groups after their stratification by age of disease onset, clinical course, or response to therapy. In conclusion, CTLA-4 exon 1 49 A>G polymorphism is not associated with susceptibility to ITP in the Egyptian population; neither it affects the clinical picture of the disease. |
(1)100 *null* | (17)4 (PD) | (33)3 to | (49)2 condition, |
(2)39 and | (18)4 activity | (34)2 (CHD) | (50)2 development |
(3)16 is | (19)4 outcome | (35)2 (COPD) | (51)2 interval |
(4)13 in | (20)4 severity, | (36)2 (CVD), | (52)2 many |
(5)12 of | (21)4 the | (37)2 (GERD) | (53)2 multi-sectoral |
(6)9 (FMD) | (22)4 who | (38)2 (LSD) | (54)2 on |
(7)8 risk | (23)3 (CAD) | (39)2 (SC) | (55)2 onset |
(8)7 severity | (24)3 compared | (40)2 Control | (56)2 onset, |
(9)6 progression | (25)3 control | (41)2 activity, | (57)2 outbreaks |
(10)6 that | (26)3 course | (42)2 are | (58)2 patterns |
(11)6 was | (27)3 free | (43)2 as | (59)2 phobia |
(12)5 (CVD) | (28)3 has | (44)2 associated | (60)2 prevention |
(13)5 or | (29)3 management | (45)2 burden | (61)2 processes |
(14)5 state | (30)3 may | (46)2 by | (62)2 progression, |
(15)4 (AD) | (31)3 patients | (47)2 can | (63)2 surveillance |
(16)4 (HD) | (32)3 states | (48)2 characterized | (64)2 usually |
add keyword